AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

Post-LOESM

amlodipine besylate; hydrochlorothiazide; valsartan

Teva

ANDAORALTABLET

Approved

Jun 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE (amlodipine besylate; hydrochlorothiazide; valsartan) by Teva is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Approved for hypertension, to lower blood pressure, confirmed and 5 more indications. First approved in 2015.

Drug data last refreshed 19h ago

Mechanism of Action

(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…

Indications (7)

Worked on AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.